Communiqués RAPT Therapeutics, Inc.

Actions

RAPT

US75382E1091

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
3,84 ^USD	-4,71 %		-4,24 %	-84,55 %

14/05	RAPT THERAPEUTICS, INC. : Wolfe Research dégrade son opinion à neutre	ZM
10/05	RAPT THERAPEUTICS, INC. : Guggenheim abaisse son opinion à neutre	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

RAPT Therapeutics Reports First Quarter 2024 Financial Results	09/05	GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04	GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	11/03	PR
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03	GL
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03	AQ
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03	GL
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	03/03	PR
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	26/02	BU
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon	20/02	GL
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations	13/02	GL
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations	13/02	AQ
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01	GL
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	GL
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	02/01	AQ
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy	27/11	GL
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy	27/11	AQ
RAPT Therapeutics Reports Third Quarter 2023 Financial Results	13/11	GL
RAPT Therapeutics Reports Third Quarter 2023 Financial Results	13/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués RAPT Therapeutics, Inc.

Actions

RAPT

US75382E1091

Communiqués

Filtres